Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Validation Study of Analytical Methods for Multiparameter Flow Cytometry-Based Measurable Residual Disease Assessment in Acute Myeloid Leukemia

8 May 2025

Abstract excerpt

The standardization of multiparameter flow cytometry-based measurable residual disease (MFC-MRD) assessment in acute myeloid leukemia (AML) lacks clear criteria to define leukemia-associated immunophenotypes (LAIPs). In addition, the most specific/sensitive aberrations used to define LAIPs are often partially expressed by the leukemic clone at diagnosis, raising questions about their reliability for accurate MRD...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Myeloid Leukemia Research
Share to Cancer Genomics and Diagnostics
Share to Single-cell and spatial transcriptomics

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 40429651
DOI: 10.3390/ijms26104506

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Validation Study of Analytical Methods for Multiparameter Flow Cytometry-Based Measurable Residual Disease Assessment in Acute Myeloid LeukemiaPMID 40429651Read ↗

Identification of leukemia-associated immunophenotypes by database-guided flow cytometry provides a highly sensitive and reproducible strategy for the study of measurable residual disease in acute myeloblastic leukemiaSemantic proximity Read ↗

Pattern associated leukemia immunophenotypes and measurable disease detection in acute myeloid leukemia or myelodysplastic syndrome with mutated NPM1Semantic proximity Read ↗

Prognostic and Therapeutic Implications of Measurable Residual Disease Detection Across Hematologic Malignancies: Clinical Impact on Relapse Prediction and Survival OutcomesSemantic proximity Read ↗

Minimal Residual Disease Detection in Acute Lymphoblastic LeukemiaSemantic proximity Read ↗

Real-World Outcomes in NPM1-Mutated Acute Myeloid Leukemia: The Impact of Measurable Residual Disease on Disease Relapse.Semantic proximity Read ↗

Stability of leukemia‐associated aberrant immunophenotypes in patients with acute myeloid leukemia between diagnosis and relapse: Comparison with cytomorphologic, cytogenetic, and molecular genetic findingsSemantic proximity Read ↗

Leukemia‐associated immunophenotypes subdivided in “categories of specificity” improve the sensitivity of minimal residual disease in predicting relapse in acute myeloid leukemiaSemantic proximity Read ↗

Molecular measurable residual disease monitoring and transplant indications in NPM1 mutated acute myeloid leukemia.Semantic proximity Read ↗

Measurable residual disease detected by flow cytometry independently predicts prognoses of NPM1-mutated acute myeloid leukemia.Semantic proximity Read ↗

Comparison between multiparameter flow cytometry and WT1-RNA quantification in monitoring minimal residual disease in acute myeloid leukemia without specific molecular targetsSemantic proximity Read ↗

Measurable Residual Disease at Induction Redefines Partial Response in Acute Myeloid Leukemia and Stratifies Outcomes in Patients at Standard Risk Without NPM1 Mutations.Semantic proximity Read ↗

Minimal residual disease in acute myelogenous leukemia.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.